Related Experiment Videos
L-arginine therapy in Raynaud's phenomenon?
A Agostoni1, B Marasini, M L Biondi
1Department of Clinical Medicine, University of Milan, S. Paolo Hospital, Italy.
International Journal of Clinical & Laboratory Research
|January 1, 1991
Summary
L-Arginine treatment improved digital vascular response in patients with Raynaud's phenomenon secondary to systemic sclerosis. This therapy enhanced vasodilation and increased tissue-type plasminogen activator levels.
Area of Science:
- Vascular Biology and Medicine
- Rheumatology
- Pharmacology
Background:
- Raynaud's phenomenon involves impaired digital vascular response to stimuli.
- L-Arginine is a precursor to nitric oxide, a key vasodilator.
- Systemic sclerosis is a common cause of secondary Raynaud's phenomenon.
Purpose of the Study:
- To investigate the effects of L-Arginine treatment on digital vascular response in patients with Raynaud's phenomenon.
- To assess changes in vasodilation and related markers after L-Arginine therapy.
Main Methods:
- Patients with primary or secondary Raynaud's phenomenon received L-Arginine treatment.
- Digital vascular response was evaluated using local warming and cold stimuli.
- Plasma levels of tissue-type plasminogen activator were measured.
Main Results:
- L-Arginine therapy led to higher digital vasodilation after local warming in patients with secondary Raynaud's phenomenon.
- Improved cold-induced digital vasodilation was observed.
- Plasma levels of tissue-type plasminogen activator increased post-treatment.
Conclusions:
- L-Arginine treatment positively impacts digital vascular function in Raynaud's phenomenon secondary to systemic sclerosis.
- The findings suggest L-Arginine may be a beneficial therapeutic agent for improving circulation in these patients.